Please login to the form below

Not currently logged in
Email:
Password:

BioCryst Appoints new senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals hires Dr Elliott T Berger as senior vice-president of regulatory affairs

US-based BioCryst Pharmaceuticals has hired Dr Elliott T Berger as senior vice-president of regulatory affairs.

Dr Berger brings to BioCryst a long and successful track record in obtaining approval from the FDA for numerous drugs. He will play an integral role in BioCryst's planned clinical research programmes for treatments for influenza, leukaemia and lymphoma, autoimmune diseases and transplant rejection, and will work in close collaboration with health authorities in the US and other countries.

Berger has more than 30 years of experience in the pharmaceutical industry, including over 25 years devoted to management of regulatory affairs supporting new drug and biologic development. Most recently he was vice-president of regulatory affairs and quality assurance and head of global regulatory strategy at EMD Pharmaceuticals, the North American subsidiary of Germany-headquartered Merck KGaA.

Berger held a variety of research positions at Merck Research Laboratories in West Point, Pennsylvania, most recently as Senior Director, Regulatory Liaison. He has submitted and managed over 10 New Drug Applications and numerous Investigational Drug Applications in the areas of oncology, diabetes, cardiovascular disease, and neurology.

8th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics